Pacific Biosciences of California (PACB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pacific Biosciences of California (PACB) has a cash flow conversion efficiency ratio of 2.417x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-80.27 Million) by net assets ($-33.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Pacific Biosciences of California worth for the company's overall valuation and market capitalisation.
Pacific Biosciences of California - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Pacific Biosciences of California's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pacific Biosciences of California Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pacific Biosciences of California ranked by their cash flow conversion efficiency. Explore PACB cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fujian Oriental Silver Star Investment Co Ltd
SHG:600753
|
-0.095x |
|
BTS Group AB (publ)
ST:BTS-B
|
-0.041x |
|
Organización Cultiba S.A.B. de C.V
MX:CULTIBAB
|
-0.023x |
|
Patrimoine et Commerce SA
PA:PAT
|
0.036x |
|
Sichuan Dawn Precision Technology Co Ltd
SHE:300780
|
0.037x |
|
Yest Ltd
KQ:122640
|
-0.029x |
|
Q2 METALS CORP.
F:458
|
-0.006x |
|
Apogee Optocom Co Ltd
TW:6426
|
0.021x |
Annual Cash Flow Conversion Efficiency for Pacific Biosciences of California (2008–2025)
The table below shows the annual cash flow conversion efficiency of Pacific Biosciences of California from 2008 to 2025. View PACB share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.35 Million | $-111.21 Million | -20.791x | -5011.38% |
| 2024-12-31 | $506.59 Million | $-206.06 Million | -0.407x | -7.02% |
| 2023-12-31 | $701.30 Million | $-266.55 Million | -0.380x | +18.72% |
| 2022-12-31 | $562.90 Million | $-263.21 Million | -0.468x | -232.67% |
| 2021-12-31 | $790.99 Million | $-111.18 Million | -0.141x | -341.79% |
| 2020-12-31 | $335.49 Million | $19.50 Million | 0.058x | +104.08% |
| 2019-12-31 | $54.92 Million | $-78.31 Million | -1.426x | -144.85% |
| 2018-12-31 | $114.06 Million | $-66.43 Million | -0.582x | +25.73% |
| 2017-12-31 | $86.10 Million | $-67.52 Million | -0.784x | +2.26% |
| 2016-12-31 | $84.67 Million | $-67.93 Million | -0.802x | -23.20% |
| 2015-12-31 | $73.54 Million | $-47.89 Million | -0.651x | +30.48% |
| 2014-12-31 | $54.95 Million | $-51.47 Million | -0.937x | -117.20% |
| 2013-12-31 | $69.18 Million | $-29.83 Million | -0.431x | +38.60% |
| 2012-12-31 | $109.38 Million | $-76.82 Million | -0.702x | -30.59% |
| 2011-12-31 | $191.46 Million | $-102.97 Million | -0.538x | -23.38% |
| 2010-12-31 | $279.87 Million | $-122.00 Million | -0.436x | -203.17% |
| 2009-12-31 | $-177.12 Million | $-74.84 Million | 0.423x | +3.02% |
| 2008-12-31 | $-93.39 Million | $-38.30 Million | 0.410x | -- |
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stran… Read more